Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers

  • Bioorg Med Chem Lett. 2012 Sep 1;22(17):5618-24. doi: 10.1016/j.bmcl.2012.06.105.
Inger Kers  1 ,  Gabor Csjernyik ,  Istvan Macsari ,  Martin Nylöf ,  Lars Sandberg ,  Karin Skogholm ,  Tjerk Bueters ,  Anders B Eriksson ,  Sandra Oerther ,  Per-Eric Lund ,  Elisabet Venyike ,  Jan-Erik Nyström ,  Yevgeni Besidski
Affiliations
  • 1. Medicinal Chemistry, CNSP iMed Science, AstraZeneca R&D, Innovative Medicines, SE-15185 Södertälje, Sweden. [email protected]
PMID: 22832315 DOI: 10.1016/j.bmcl.2012.06.105
Abstract

Recent findings showing a relation between mutations in the Na(V)1.7 channel in humans and altered pain sensation has contributed to increase the attractiveness of this ion channel as target for development of potential analgesics. Amido chromanes 1 and 2 were identified as blockers of the Na(V)1.7 channel and analogues with modifications of the 5-substituent and the carboxamide part of the molecule were prepared to establish the structure-activity relationship. Compounds 13 and 29 with good overall in vitro and in vivo rat PK profile were identified. Furthermore, 29 showed in vivo efficacy in a nociceptive pain model.

Products